Proalid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proalid

Property Description
Active ingredient Tacrolimus (INN)
Form Ointment (anhydrous)
Pharmacological class Topical Calcineurin Inhibitor (TCI)
General purpose Localized Immunomodulation / Anti-inflammatory effect
Origin Derived from Streptomyces tsukubaensis (biological macrolide structure)

1. What Type of Medicine is Proalid and Its Pharmacological Classification?

Proalid is a prescription-only dermatological medicine formulated as an ointment for topical use. Its active ingredient is Tacrolimus (INN), which is classified as a macrolide immunosuppressant belonging to the distinct pharmacological class of Topical Calcineurin Inhibitors (TCIs). This classification establishes Proalid as a non-steroidal treatment, providing a therapeutically recognized alternative for managing localized inflammatory skin conditions.

The use of this drug class is clinically recognized for its ability to modulate specific immune responses without the systemic characteristics of traditional steroid hormones. Proalid provides a crucial mechanism that targets the immune system within the skin layers.


2. Proalid Composition and General Therapeutic Purpose

The preparation is an anhydrous ointment intended for external application, containing the single active substance, Tacrolimus, suspended within a dermatological base of components like mineral oil and white petrolatum. The Tacrolimus molecule is a macrolide lactam derived from a biological origin, specifically the fermentation process of the bacterium Streptomyces tsukubaensis.

The primary purpose of Proalid is to act as an immunomodulator to interrupt the local inflammatory cycle. By interfering with the immune processes that drive irritation, it achieves localized anti-inflammatory relief. The general benefit is the suppression of immune signals at the site of application, relieving persistent symptoms like swelling, redness, and irritation.

What side effects are possible with Proalid?

Safety Profile Overview

Proalid (tacrolimus) is a potent immunosuppressant, and its safety profile is defined by risks common to this class of medication, particularly increased susceptibility to infections and the development of certain malignancies.

Documented Adverse Reactions

Adverse reactions associated with Proalid therapy are categorized by frequency, with many being very common across various transplant populations. Major categories of concern documented in regulatory texts include Infections and Infestations, Nephrotoxicity (kidney damage), Neurotoxicity (nervous system effects), and Malignancies.

Frequency Examples of Very Common Adverse Reactions
Very Common (Affects more than 1 in 10 people) Tremor, headache, diarrhea, nausea, hypertension, insomnia, hypomagnesemia, hyperkalemia, abnormal kidney function, and fever.

Clinically Significant and Serious Risks

Serious Infections: Use of Proalid increases the risk of serious bacterial, viral, fungal, and protozoal infections, including opportunistic infections and viral reactivation (e.g., Polyoma Virus Infections like PVAN).

Malignancies: There is an increased risk of developing lymphoma (including Post-transplant Lymphoproliferative Disorder, PTLD) and other malignancies, particularly skin cancer, with the intensity and duration of use being risk factors.

Organ-Specific Toxicity: Both Nephrotoxicity (potentially severe) and Neurotoxicity (which can manifest as tremor, seizures, or Posterior Reversible Encephalopathy Syndrome—PRES) are major documented risks. Other serious risks include New Onset Diabetes After Transplant (NODAT) and hyperkalemia.

Safety Considerations

Patients with impaired hepatic or renal function may require specific dose adjustments. Grapefruit juice must be avoided due to the potential for clinically significant drug interactions that can increase Proalid concentrations. Because of the risk of developing skin malignancies, patients should minimize exposure to UV light and sunlight.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The official regulatory documents for Tacrolimus Ointment define the overdose profile primarily around the risk of accidental oral ingestion.


Documented Overdose Profile

Domain Statement Based on Regulatory Labels
Exposure Risk Systemic toxicity is unlikely to occur from excessive topical application due to the low rate of skin absorption. The main concern is accidental oral ingestion.
Severe Outcomes Significant systemic exposure from ingestion may lead to impaired renal function (nephrotoxicity) and, in some cases, neurological symptoms.
Antidote Status No specific antidote is known for Tacrolimus.
Management Treatment is strictly symptomatic and supportive. Dialysis is ineffective for enhancing elimination.

Required Emergency Action

Regulators mandate that patients seek immediate medical attention or contact a poison control center for any known or suspected accidental ingestion of the ointment. Urgent hospitalization and comprehensive medical support may be required, particularly if systemic effects, such as signs of renal impairment, are suspected. Medical professionals may consider procedural steps like gastric lavage or the use of activated charcoal shortly after ingestion to limit absorption.

Therapeutic Uses of Proalid

What Proalid Treats: Main Uses and Benefits

Symptomatic Relief and Stability

The medication is used to help manage symptoms in chronic inflammatory skin conditions, such as atopic dermatitis (eczema). It is utilized for treating the symptoms of this condition across domains where additional symptomatic support is needed, primarily targeting the distressing symptoms of intense, persistent itching and associated irritation. It is commonly used to manage the visible manifestations of inflammation, including redness, swelling, and scaly or thickened patches.

“It is considered relevant for easing pronounced symptoms and can support the patient's day-to-day comfort during episodes of heightened skin distress.”

This supportive action contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Quick Fact: Relevant for Easing Intense Itching


Controlling Acute Flare-Ups

Proalid is relevant in conditions characterized by periods of heightened symptoms. The medication is often applied during phases when symptoms become more noticeable (flare-ups) and supportive relief is appropriate for managing symptom fluctuations. By assisting with the management of these acute or disruptive episodes, the medication supports patients during periods of heightened discomfort and helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Who Can and Cannot Use Proalid?

The use of Proalid (Tacrolimus Ointment) is strictly defined by official regulatory guidelines concerning patient history, age, and immune status.


Absolute Non-Eligibility

The medicine is strictly contraindicated in patients with a known history of hypersensitivity to the active ingredient tacrolimus, to the macrolide drug class in general, or to any component of the ointment. Use is also prohibited in patients with congenital or acquired immunodeficiencies and in those receiving systemic immunosuppressive therapy. Application must also be avoided on potentially malignant or pre-malignant skin lesions.


Age-Group Eligibility Rules

  • The medicine is not recommended for children younger than 2 years of age.
  • Children aged 2 to 15 years are restricted to using only the 0.03% strength ointment.
  • Adults and adolescents (16 years and older) may use either the 0.03% or 0.1% strength. Use in older adults does not require specific dose adjustment.

Specific Regulatory Restrictions

Use is formally not recommended during pregnancy due to a lack of adequate safety studies. For lactating women, the label requires a decision to discontinue nursing or discontinue the drug. Furthermore, continuous long-term use must be avoided in all patient groups; treatment is only for short-term and intermittent use. Caution is advised for patients with severe hepatic or renal impairment.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Proalid

Interaction scope

Property Details
Medicinal product categories with documented interactions CYP3A4 Inhibitors (known to inhibit the enzyme responsible for tacrolimus metabolism).
Specific interacting medicines (if explicitly listed) Examples of CYP3A4 inhibitors (e.g., Erythromycin, Itraconazole) and Alcohol (Ethanol).
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction driven by inhibition of Cytochrome P450 3A4 (CYP3A4), which reduces clearance and increases systemic concentration. A specific pharmacodynamic interaction exists with alcohol.
Timing-based interaction rules (if applicable) Emollients must be applied to the same area of skin with a mandatory 2-hour separation interval from the ointment application.
Population-specific interaction notes (if applicable) Risk is heightened for patients with widespread and/or erythrodermic disease. Caution is noted for patients with hepatic failure.
Interaction-related restrictions Caution is advised regarding the systemic co-administration of known CYP3A4 inhibitors when treating large or compromised skin surface areas. Co-use with Grapefruit/Grapefruit Juice is cautioned due to CYP3A4 inhibition risk.

Interaction classifications (high-level)

Property Classification / Description
Interaction severity classification (as defined in official documents) Use-with-caution combination for systemic CYP3A4 inhibitors; Documented substance interaction for alcohol; Mandatory administration separation for emollients.
Regulatory basis (EMA / FDA / etc.) U.S. Food and Drug Administration, European Medicines Agency, National Institutes of Health MedlinePlus.
Interaction-context constraints (as defined in official documents) The primary constraint on pharmacokinetic interactions is the condition of the skin, which affects the likelihood of systemic absorption.

Resulting interaction structure

Official interaction statements:

  • Co-administration of known CYP3A4 inhibitors may increase systemic exposure of tacrolimus.
  • This pharmacokinetic interaction risk is of specific concern for patients being treated over widespread and/or erythrodermic disease skin surfaces.
  • Emollients must not be applied to the same area of skin within 2 hours of applying the ointment.
  • Consumption of alcohol is officially documented to cause a specific reaction characterized by facial flushing or skin irritation.
  • Caution is advised in patients with hepatic failure due to the extensive metabolism of tacrolimus in the liver.

Connection to the overall interaction profile: The product's interaction structure is defined by two distinct regulatory constraints: a pharmacokinetic caution tied to the potential for systemic exposure (absorption risk mediated by CYP3A4 inhibitors) and explicit administration timing rules for co-applied topical products (emollients). This structure dictates the documented restrictions based on the patient's skin condition and simultaneous use of specific enzyme inhibitors, alongside a notable substance interaction with alcohol.

Mechanism of Action

Proalid is a novel pharmacological agent that exerts its effect primarily by targeting the mevalonate pathway, a critical metabolic route responsible for synthesizing sterol and non-sterol isoprenoids. Proalid functions as a specific, competitive inhibitor of farnesyl pyrophosphate synthase (FPPS). By blocking FPPS, Proalid prevents the conversion of geranyl pyrophosphate (GPP) to farnesyl pyrophosphate (FPP), thereby arresting the intermediate steps necessary for downstream synthesis.

This inhibition of the mevalonate pathway cascade leads to a significant decrease in the production of crucial isoprenoid lipids, such as geranylgeranyl pyrophosphate (GGPP) and FPP. These lipids are essential for a post-translational modification process known as protein prenylation. Specifically, FPP and GGPP are required for the farnesylation and geranylgeranylation of small signaling proteins, including members of the Ras and Rho GTPase families.

The consequential lack of prenylation prevents these GTPases from correctly associating with the cell membrane, which is necessary for their activation. By modulating the membrane localization and thus the activity of these signaling proteins, Proalid influences downstream cellular functions, including regulation of cell-cycle progression, cell differentiation, and cytoskeletal organization, resulting in a systemic physiological consequence of altered cellular signaling and proliferation control.

Dosage and Administration Information

How to Use Proalid: Official Administration Guidelines

Proalid (Tacrolimus Ointment) is intended strictly for topical administration to the skin surface. The usage protocol is divided into two distinct phases: acute treatment and maintenance therapy, utilizing different frequencies.

For acute treatment of affected areas, the ointment is typically applied twice daily (approximately every 12 hours) until the symptoms are cleared or significantly improved. When used for maintenance therapy, the frequency shifts to twice weekly application on areas previously affected by the condition, supporting long-term stability and preventing recurrence of symptoms. Usage is intended to be intermittent and non-continuous over a long period.

Dosing and Application Rules

Population Approved Strength Frequency Pattern
Adults (≥16 years) 0.1% Ointment Acute: Twice Daily / Maintenance: Twice Weekly
Pediatric (2–15 years) 0.03% Ointment Acute: Twice Daily / Maintenance: Twice Weekly

The application method requires applying only a thin layer sufficient to cover the affected skin area. Guidelines specify that occlusive dressings, such as bandages or wraps, must not be used over the treated area. If an application is missed, it should be applied as soon as it is remembered, with the normal schedule resuming afterward. Safety and efficacy have not been established for use in children under 2 years of age.

Recent Clinical Evidence

Research evidence / Overview of Studies for Proalid

This overview summarizes the available research regarding Proalid, focusing only on the types of studies that have been conducted, the populations examined, and what findings were described in regulatory and peer-reviewed literature. This information is descriptive and does not constitute clinical advice or recommendations.


Evidence for Use in Atopic Dermatitis (Eczema)

The majority of the evidence for Proalid was studied for atopic dermatitis, a condition characterized by fluctuating or episodic manifestations such as persistent itching, redness, and inflammation. Research monitored the short-term and long-term changes in these specific symptoms.

Short-Term Comparative Trials

Research examined the medicine primarily through short-term Randomized Controlled Trials (RCTs), which are considered the highest standard for measuring initial clinical outcomes. These trials compared Proalid against a non-medicated ointment (vehicle) and against other topical comparators. The outcomes measured included standardized clinical assessments (e.g., EASI and IGADA) and patient-reported outcomes describing perceived discomfort. Systematic reviews combining the results of these trials findings indicate patterns related to changes in these standardized scores across the observed populations.

Studies Tracking Disease Exacerbation

Beyond the initial short-term assessment of acute symptoms, research examined how Proalid was observed in long-term protocols aimed at tracking consistency of skin condition. These open-label studies monitored the frequency and duration of disease exacerbations or "flare-ups" over several months and, in some cases, years. Findings describe patterns observed in the studies where certain regimens were associated with observations of sustained status within the study cohorts.


Evidence in Special Populations and Uncertainties

Research examined patients across the age spectrum. The 0.03% concentration was evaluated in children age 2 and older, while the 0.1% concentration was evaluated in adults age 16 and older with moderate to severe atopic dermatitis. Research focusing on the 0.1% concentration is not available for children under the age of 16.

Long-term data covering up to 10 years of use is derived from non-randomized, observational studies. The follow-up durations were limited in many of the initial comparative RCTs. Therefore, there is limited information for long-term outcomes from randomized, highly controlled settings, meaning data are still emerging regarding definitive conclusions about long-term outcomes.

Key Studies & References

  1. Long-term Safety and Efficacy of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Children (Observational safety data and maintenance phase details)
  2. The impact of tacrolimus therapy on the outcomes of vernal keratoconjunctivitis: a systematic review and meta-analysis (Evidence for chronic allergic eye diseases, including VKC)

Frequently Asked Questions (FAQ)

Common questions about Proalid (FAQ)


Q: How quickly should I expect to notice anything after starting Proalid?

Clinical studies and official information noted that a pattern of improvement was generally observed within one week of beginning the application in study participants. If signs of improvement are not observed after two weeks of acute treatment, official guidelines describe that a healthcare provider typically reviews the continuation of the treatment.


Q: Are there any common supplements that should not be taken with Proalid?

Regulatory documents advise patients to inform their healthcare provider about all medicines, vitamins, and herbal supplements they use. Although this is a topical medicine, the systemic form of the active ingredient interacts with the herbal supplement St. John’s Wort, and its use is cautioned against because of the potential for pharmacokinetic interactions that might affect the medicine’s concentration.


Q: Is it true that Proalid can cause hair loss?

The most common side effects listed for the topical ointment are application-site reactions like burning and itching. While hair loss (alopecia) has been reported as an adverse reaction for the oral (systemic) form of the active ingredient, it is not listed among the very common side effects for the topical ointment.


Q: Is it normal to feel tired in the first week of taking Proalid?

Feeling tired is not listed among the most frequently reported adverse events for the ointment. Less common side effects, such as flu-like symptoms which may include fatigue, are sometimes noted in reports, but these are typically not considered one of the defining side effects of the topical treatment.


Q: Does Proalid interact with common pain relievers like ibuprofen?

Official information notes that the active ingredient is associated with a risk of kidney problems (nephrotoxicity). Due to this potential, official information notes that a healthcare provider may need to consider the concurrent use of other medicines, such as ibuprofen, that are known to also affect kidney function.


Q: Can Proalid be taken with food, or does it need to be taken on an empty stomach?

Proalid is formulated as a topical ointment that is applied directly to the skin. Since it is not swallowed or taken by mouth, there are no official instructions regarding food intake or an empty stomach that apply to its use.


Q: Are the side effects of Proalid permanent?

The most common local side effects, such as a burning sensation and itching, are generally transient and reported to improve within the first week of use. However, the medicine carries a warning related to long-term risks, such as malignancies (cancers), which are not temporary.


Q: Does Proalid affect my ability to drive or operate machinery?

Official product information indicates that systemic absorption from the topical application is typically minimal. Therefore, any effects on your ability to drive or safely operate heavy machinery are considered unlikely.


Q: What is the risk of stopping Proalid suddenly?

Official guidelines describe that treatment is stopped when the skin lesions are cleared or almost cleared. Regulatory documents do not warn of a specific withdrawal syndrome or 'rebound' effect resulting from stopping the treatment when the condition has resolved, as directed by the label.


Q: Do I need special monitoring or blood tests while taking Proalid?

Because the medicine is applied topically, systemic absorption is usually very low. Routine monitoring of blood levels is not generally required for most patients using the ointment. However, monitoring may be considered for individuals being treated over widespread areas of affected skin.


Q: Can Proalid affect fertility in men or women?

Non-clinical safety studies of the active ingredient, when given systemically in high doses to animals, have shown some potential for reproductive toxicity. Official information describes that the relevance of this finding to human fertility when using the topical ointment is not fully established, given its minimal absorption.


Q: How long does Proalid stay in your system after stopping it?

Systemic exposure from the topical ointment is minimal and tends to decline as the skin barrier function improves and heals. Clinical studies show no evidence of systemic accumulation (build-up in the body) when the ointment is used intermittently as prescribed.


Q: Is it safe to exercise heavily while taking Proalid?

Official patient information states that limiting sun exposure and protecting treated skin areas from ultraviolet (UV) light is necessary. Because there is a need to minimize sun exposure, outdoor physical activity may require specific protective measures for the treated areas.


Q: Why do some people experience initial worsening of symptoms on Proalid?

The most common adverse events are local application site reactions, specifically burning, itching, and redness at the site of application. These reactions are typically a transient side effect in the first week of use and may sometimes be mistaken for an initial worsening of the underlying condition.


Q: Does Proalid interact with herbal products like St. John's Wort?

The systemic form of the active ingredient interacts with St. John’s Wort; regulatory documents describe that its use is cautioned against. St. John’s Wort is noted for affecting the breakdown of certain medicines, and its use is cautioned against due to the possibility of reducing the medicine's effectiveness.


Q: Are generic versions of Proalid available?

Yes, regulatory agencies have approved generic versions of tacrolimus ointment. These generic formulations have been determined to be therapeutically equivalent to the brand-name product.


Q: Does Proalid help with other symptoms besides the main condition?

According to regulatory documents, Proalid is only indicated for the treatment of moderate to severe atopic dermatitis in specific patient groups. Use for other symptoms or conditions is not covered by official labeling.


Q: What should I do if I get a rash while taking Proalid?

Rash is listed as a potential side effect associated with the use of the medicine. If your symptoms worsen, or if you develop signs of a skin infection, official guidance states that a patient should contact their doctor or healthcare provider for further evaluation.


Q: What is the typical time frame for the benefits of Proalid to peak?

Clinical trial data described that a pattern of significant improvement was observed in the 0.1% group by Week 3 of treatment. Continued use according to the prescribed regimen supports long-term stability and prevention of recurrence.


Q: Do the side effects get better over time?

Common local side effects such as burning, itching, and redness are reported to be transient in nature. In clinical summaries, these reactions usually lessen or resolve within the first week of continuous application.


Q: Can Proalid cause weight changes?

Weight changes (both gain and loss) are listed as adverse reactions for the systemic (oral) form of the active ingredient. However, due to minimal absorption, weight changes are not commonly listed as side effects for the topical ointment.


Q: Is Proalid considered a Schedule II substance?

Proalid (tacrolimus) is a prescription medicine but is not listed under any drug scheduling classification (such as Schedule I, II, III, IV, or V) by regulatory bodies like the U.S. Drug Enforcement Administration (DEA).

How should Proalid be stored and disposed of?

Storage and Disposal of Proalid (Tacrolimus Ointment)

Proalid Ointment must be stored according to regulatory labeling to maintain its stability.

Official Storage Requirements

  • Temperature: Store at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F). Temperatures must not exceed this range for long periods, and the product must not be frozen.
  • Protection: The ointment must be kept away from light and moisture.
  • Container: Store the medicine in its original container and ensure the tube is tightly closed after each use.
  • Child Safety: The product must be stored strictly out of the reach of children.

Disposal Instructions

Unused or expired Proalid should be disposed of properly. Regulatory guidelines state that the ointment must not be flushed down the toilet or poured into a drain. The official preferred method is to utilize a community drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed container before discarding in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proalid found in:

A-Z Index: